teclistamab
janssen,genmab
['cart,(-cartitude)', 'teclistamab']
teclistamab sc showed a response rate of 63%, mrd- 27% at 10-5 via ngs, crs ~70% (grade 1/2), icans 3 % (grade 1/2),median pfs 11.3 months, median dor 18.4 months, median follow-up 14 months. #cartsm #asco22 #asco22_szu #mediq22asco #eha2022
Chief of Myeloma @MSKCancerCenter | Chair @ALLIANCE_org #mmsm Comm. |Physician ? Provider| @ASH_hematology @ASTCT @ASCO |married to @ZainabShd | #BMTsm #CARTsm